JPRN-UMIN000010055
Recruiting
Phase 2
Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy - Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy
Respiratory Center, Showa University Northern Yokohama Hospital0 sites20 target enrollmentFebruary 18, 2013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Respiratory Center, Showa University Northern Yokohama Hospital
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with symptomatic brain metastases. 2\. Patients with history or complication of hemoptysis. \*Definition of hemoptysis is determined by the following. A history of continuous hemoptysis over one week, or hemoptysis receiving oral or intravenous hemostatic medicine. 3\. Patients with a history of severe drug allergy. 4\. Patients with uncontrolled ascites, pleural effusion, or pericardial effusion 5\. Patients with a history of gastrointestinal perforation within an year, or a complication of uncontrollable peptic ulcer. 6\. Patients with uncontrolled hypertension 7\. Patients with infectious disease requiring systemic administration of antiviral agents, antifungal agents, or antibiotics. 8\. Patients receiving anticoagulant therapy 9\. Patients receiving antiplatelet therapy \*Patients receiving aspirin therapy up to 325mg are allowed to be registered. 10\. Patients with a history of radiation to the chest, or more than 20% region of bones with hematopoietic ability 11\. Patients with multiple cancers within 5years prior to initiation of the study, except for carcinoma in situ, mucosal cancer appropriately treated non\-melanoma, cervical cancer, thyroid cancer, early gastric cancer, early colorectal cancer. 12\. Patients with serious complications (such as heart disease, active infection, interstitial pneumonia, diabetes) 13\. Pregnant woman or those with suspected pregnancy, nursing woman and those who plan to become pregnant during the study period. 14\. Other patients whom the investigation considers to be unsuitable for participation in the study. 15\. Patients treated with EGFR\-TKI
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study of multimodality treatment for ATRTAtypical teratoid rhabdoid tumorD016543JPRN-jRCTs051200071Junichi Hara50
Recruiting
Phase 2
Phase II study of new risk classification and high-dose chemotherapy for medulloblastomaJPRN-jRCTs051200021Hara Junichi229
Not yet recruiting
Phase 2
Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.esophageal cancer, gastric cancer, small bowel cancer, colon cancer, pancreatic cancerJPRN-UMIN000049555ational Cancer Center Hospital30
Recruiting
Phase 2
Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositisJPRN-jRCTs062220023Takano HIdeyuki50
Not yet recruiting
Not Applicable
Phase II study to evaluate the safety and efficacy of endoscopic radiofrequency ablation of the bile duct using the Habib Endo HPB catheter in patients with unresectable cholangiocarcinoma after biliary stent placement.CholangiocarcinomaJPRN-UMIN000047127Yokohama City University10